Short answer
Bio-rad Laboratories Inc (BIO) filed its Q3 2017 10-Q quarterly report on Nov 9, 2017 for the quarter ended Sep 30, 2017.
Bio-rad Laboratories Inc Q3 2017 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $535.0M, up 5.2% YoY from $508.7M
- Gross margin 56.9% vs 54.9% YoY, net margin 5.1% vs 3.6%
- Best segment: Life Science revenue $193.6M, up 8.7%; Clinical Diagnostics $338.0M, up 3.3%
- Operating cash flow $34.5M vs $121.3M YoY; cash, equivalents and investments $716.5M
- RainDance acquisition cash payment $72.9M; GnuBIO closure charges $8.4M
- Headwinds: government spending constraints, currency exposure and uncertain global economic outlook
Risk Factors
- New financial-reporting risk: ERP conversion created a material weakness after data-migration errors in Europe during third-quarter 2017
- ERP deployment risk: Western Europe launch in April 2017 delayed vendor payments, product availability, shipments, and sales
- Regulatory risk: European Parliament approved stricter in-vitro diagnostic and medical-device rules in April 2017
- Market risk: Foreign subsidiaries generated 61% of net sales, exposing results to U.S. dollar strengthening
- Financial risk: $434.9 million outstanding debt plus a $200.0 million revolving facility subject to leverage and interest-coverage covenants
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Bio-rad Laboratories Inc quarterly reports
- Q3 2019 10-QFiled Nov 1, 2019
- Q2 2019 10-QFiled Aug 6, 2019
- Q1 2019 10-QFiled May 10, 2019
- Q3 2018 10-QFiled Nov 5, 2018
- Q2 2018 10-QFiled Aug 9, 2018
- Q1 2018 10-QFiled May 10, 2018
- Q2 2017 10-QFiled Aug 7, 2017
- Q1 2017 10-QFiled May 9, 2017
- Q3 2016 10-QFiled Nov 2, 2016
- Q2 2016 10-QFiled Aug 5, 2016
- Q1 2016 10-QFiled May 6, 2016
- Q3 2015 10-QFiled Nov 5, 2015
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.